Connect with us

Hi, what are you looking for?

Monday, Oct 3, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Stock News

Reunion Neuroscience starts trading on the TSX

Reunion still holds 21.84% interest in Field Trip Health & Wellness

Reunion Neuroscience now publicly traded on the TSX
Photo via Reunion Neuroscience

Reunion Neuroscience Inc. (REUN) has now completed the final step in its corporate reorganization plan, dividing the organization into two distinct sister companies.

On Wednesday, Reunion (formerly known as Field Trip Health Ltd.) announced that its common shares would begin trading on the Toronto Stock Exchange (TSX) with the ticker symbol “REUN.”

Field Trip announced that it would be changing its name to Reunion Neuroscience at the end of July and has since spun out the company’s former clinic and technology division or subsidiary — Field Trip Health & Wellness Ltd. (FTHW) into a separate stand-alone public company also traded on the TSX.

However, Reunion says it will continue to hold a 21.84 per cent interest in FTHW even though Reunion and Field Trip will now be functioning as two separate entities.

Read more: Field Trip administers new synthetic molecule in Australia

Read more: Field Trip to split into two independent companies

“We are confident that Reunion and Field Trip Health & Wellness are well positioned to operate successfully as separate companies, executing on their distinct visions and strategic priorities,” said Joseph del Moral, Co-Founder and CEO at Reunion on August 4.

“The future of both companies is exciting, with Reunion currently progressing the Phase 1 Clinical Study of FT-104, and Field Trip Health & Wellness continuing to deliver innovative psychedelic-assisted treatments,” he added.

“We believe the separation is in the best interest of shareholders and both companies, as it will allow each company to focus management efforts and capital to better execute on their own business priorities.”

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

 

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Medical and Pharmaceutical

New study also suggests that plant-derived medicines can reduce inflammation and improve mental health

M&A

'The total consideration is to be paid in a combination of cash and stock' says Irwin

Psychedelics

Shipment marks company's first successful export to Europe and second to date

Canada

Cybin will pay Mindset an initial US$500K and 'development milestone payments' that could potentially total US$9.5M afterward